GlycoMimetics, Inc. - Common Stock (NQ:GLYC)

0.1570 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GlycoMimetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Earnings Scheduled For March 27, 2024 ↗

March 27, 2024

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.

Via Benzinga

Earnings Outlook For GlycoMimetics ↗

March 26, 2024

Via Benzinga

GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts ↗

March 21, 2024

Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies.

Via Talk Markets

Earnings Outlook For GlycoMimetics ↗

November 02, 2023

Via Benzinga

GlycoMimetics: Q1 Earnings Insights ↗

May 03, 2023

Via Benzinga

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

March 13, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

February 26, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 12, 2024

From GlycoMimetics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 24, 2024

Via Benzinga

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

January 04, 2024

From GlycoMimetics, Inc.

Via Business Wire

Why Trinity Place Holdings Shares Are Trading Higher By 80%; Here Are 20 Stocks Moving Premarket ↗

January 03, 2024

Shares of Trinity Place Holdings Inc. (NYSE: TPHS) rose sharply in pre-market trading. The company reported in 8K Filing, mortgage lender agreed to extend the mortgage loan forbearance period to Jan....

Via Benzinga

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

January 03, 2024

From Apollomics Inc.

Via GlobeNewswire

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

December 10, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

November 09, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

November 03, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

October 20, 2023

From GlycoMimetics, Inc.

Via Business Wire

Earnings Scheduled For November 3, 2023 ↗

November 03, 2023

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.

Via Benzinga

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

September 06, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

September 05, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

August 02, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023

July 19, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Announces Its Addition to the Russell Microcap® Index

June 26, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

June 15, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference

May 31, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation ↗

May 09, 2023

Blood cancers such as AML, MM, and MDS affect a terrible toll on patients and their loved ones. Glycomimetics may be such a company that can offer patients suffering from various blood cancers hope...

Via Talk Markets

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023

May 03, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023

April 26, 2023

From GlycoMimetics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 29, 2023

Via Benzinga

Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 29, 2023

Gainers LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.